US Bancorp DE Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

US Bancorp DE lowered its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 8.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,186 shares of the company’s stock after selling 7,989 shares during the period. US Bancorp DE owned approximately 0.08% of MaxCyte worth $363,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its stake in MaxCyte by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company’s stock worth $93,000 after purchasing an additional 2,154 shares during the period. Rhumbline Advisers raised its stake in MaxCyte by 1.6% during the fourth quarter. Rhumbline Advisers now owns 153,655 shares of the company’s stock worth $639,000 after purchasing an additional 2,402 shares during the period. Valmark Advisers Inc. raised its stake in MaxCyte by 2.2% during the fourth quarter. Valmark Advisers Inc. now owns 115,654 shares of the company’s stock worth $481,000 after purchasing an additional 2,478 shares during the period. Verition Fund Management LLC raised its stake in MaxCyte by 39.5% during the third quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after purchasing an additional 6,045 shares during the period. Finally, Chevy Chase Trust Holdings LLC raised its stake in MaxCyte by 0.6% during the fourth quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company’s stock worth $5,574,000 after purchasing an additional 7,781 shares during the period. Hedge funds and other institutional investors own 68.81% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on MXCT. Stifel Nicolaus dropped their price objective on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday. BTIG Research set a $6.00 price objective on shares of MaxCyte and gave the stock a “buy” rating in a research report on Wednesday.

MaxCyte Trading Down 3.8 %

MXCT opened at $3.06 on Friday. The company has a fifty day simple moving average of $4.19 and a 200 day simple moving average of $3.98. The firm has a market cap of $324.23 million, a price-to-earnings ratio of -9.00 and a beta of 1.35. MaxCyte, Inc. has a twelve month low of $2.76 and a twelve month high of $5.26.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.